These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11936729)

  • 1. Chemo- and radiosensitivity testing in a patient with ataxia telangiectasia and Hodgkin disease.
    Tamminga RY; Dolsma WV; Leeuw JA; Kampinga HH
    Pediatr Hematol Oncol; 2002; 19(3):163-71. PubMed ID: 11936729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response of dermal fibroblast cultures from patients with unusually severe responses to radiotherapy and from ataxia telangiectasia heterozygotes to fractionated radiation.
    DahlBerg WK; Little JB
    Clin Cancer Res; 1995 Aug; 1(8):785-90. PubMed ID: 9816046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hodgkin disease in ataxia-telangiectasia patients with poor outcomes.
    Sandoval C; Swift M
    Med Pediatr Oncol; 2003 Mar; 40(3):162-6. PubMed ID: 12518345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of patients with advanced or bulky Hodgkin disease with a 12-week doxorubicin, bleomycin, vinblastine, and dacarbazine-like chemotherapy regimen followed by extended-field, full-dose radiotherapy: long-term results of the Groupe Ouest et Est des Leucémies et Autres Maladies de Sang H90-A/B Multicenter Randomized Trial.
    Djeridane M; Oudard S; Escoffre-Barbe M; Lacotte-Thierry L; Desablens B; Briére J; Dib M; Cassasus P; Ghandour C; Lamy T; Lejeune F; Simon M; Traullé C; Vigier M; Maisonneuve H; Briére J; Colonna P; Andrieu JM
    Cancer; 2002 Nov; 95(10):2169-79. PubMed ID: 12412171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunodeficiency and Hodgkin's disease: treatment and outcome in the DAL HD78-90 and GPOH HD95 studies.
    Niehues T; Schellong G; Dörffel W; Bucsky P; Mann G; Körholz D; Göbel U
    Klin Padiatr; 2003; 215(6):315-20. PubMed ID: 14677095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Secondary breast cancer after treatment for Hodgkin's disease. About seven cases].
    Ben Hassouna J; Slimène M; Boussen H; Bouzaiene H; Khomsi F; Chargui R; Kochbati L; Mtaallah MH; Gamoudi A; Benna F; Hechiche M; Rahal K
    Gynecol Obstet Fertil; 2007 Jun; 35(6):536-40. PubMed ID: 17543568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of preliminary results of involved-field with extended field radiotherapy combined with chemotherapy for early stage Hodgkin's disease].
    Wang WH; Li YX; Song YW; Jin J; Liu YP; Wang SL; Zhou LQ; Liu XF; Yu ZH; Han JZ
    Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):218-21. PubMed ID: 16875611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twenty-year disease and treatment-associated mortality rates of patients with Hodgkin lymphoma of clinical stages IIIB and IV prospectively treated with 3-month anthracycline-based chemotherapy followed by extended high-dose radiation.
    Sénécal D; Jais JP; Desablens B; Berthou C; Casassus P; Moles MP; Delwail V; Gastinne T; Colonna P; Andrieu JM
    Cancer; 2008 Feb; 112(4):846-55. PubMed ID: 18072259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: a Pediatric Oncology Group (POG) study.
    Tebbi CK; Mendenhall N; London WB; Williams JL; de Alarcon PA; Chauvenet AR;
    Pediatr Blood Cancer; 2006 Feb; 46(2):198-202. PubMed ID: 16136581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective study of combined modality treatment or radiotherapy alone in the management of early-stage adult Hodgkin's disease.
    Yildiz F; Zengin N; Engin H; Güllü I; Barista I; Caglar M; Ozyar E; Cengiz M; Gürkaynak M; Zorlu F; Caner B; Atahan IL; Tekuzman G
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):839-46. PubMed ID: 15465201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group.
    Eich HT; Haverkamp U; Engert A; Kocher M; Skripnitchenko R; Brillant C; Sehlen S; Dühmke E; Diehl V; Müller RP
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):860-5. PubMed ID: 15925455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
    Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus pneumonitis in a patient with Hodgkin disease and ataxia-telangiectasia.
    Sandoval C; Swift M
    Pediatr Pulmonol; 2004 Jun; 37(6):559-60. PubMed ID: 15114558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical results of 295 patients with Hodgkin's disease treated by chemotherapy-predominant comprehensive modality].
    Huang HQ; Jiang WQ; Wang W; Xu GC; Zhang L; He YJ; Sun XF; Zhou ZM; Liu DG; Xu RH; Lin TY; Teng XY; Liu MZ; Su YS; Li YH; Lin XB; Guan ZZ
    Ai Zheng; 2002 Dec; 21(12):1345-9. PubMed ID: 12520745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: cure balanced against complications.
    Koontz BF; Kirkpatrick JP; Clough RW; Prosnitz RG; Gockerman JP; Moore JO; Prosnitz LR
    J Clin Oncol; 2006 Feb; 24(4):605-11. PubMed ID: 16446333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ataxia-telangiectasia and wilms tumor: reduced treatment but early relapse.
    Pérez-Villena A; Cormenzana M; de Prada I; Pérez-Martínez A; Aleo E
    J Pediatr Hematol Oncol; 2013 May; 35(4):308-10. PubMed ID: 23612382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment results of stage IA Hodgkin lymphoma: a report of 97 cases].
    Tan WY; Hu DS; Zeng FY; Song QB; Hu S; Wei L; Zhou LQ
    Ai Zheng; 2007 Dec; 26(12):1360-4. PubMed ID: 18076802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group.
    Josting A; Nogová L; Franklin J; Glossmann JP; Eich HT; Sieber M; Schober T; Boettcher HD; Schulz U; Müller RP; Diehl V; Engert A
    J Clin Oncol; 2005 Mar; 23(7):1522-9. PubMed ID: 15632410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease.
    Hudson MM; Krasin M; Link MP; Donaldson SS; Billups C; Merchant TE; Kun L; Billet AL; Kaste S; Tarbell NJ; Howard S; Friedmann AM; Hurwitz CA; Young JA; Marcus KC; Rai S; Cowan T; Weinstein HJ
    J Clin Oncol; 2004 Nov; 22(22):4541-50. PubMed ID: 15542805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.